Russia’s Binnopharm Brings In Mabwell’s Adalimumab, Denosumab Biosimilars
Humira Biosimilar Approved In China; Prolia/Xgeva Rivals Pending Approvals
China’s Mabwell has furthered its strategy to bring its biosimilars to global markets “for the benefit of millions of patients around the world” via a licensing agreement with Russian player Binnopharm.